NWBO Northwest Biotherapeutics Inc
Price (delayed)
$0.2123
Market cap
$295.26M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.07
Enterprise value
$360.52M
Highlights
NWBO's debt is up by 48% YoY and by 16% QoQ
The equity has contracted by 44% YoY and by 18% from the previous quarter
Key stats
What are the main financial stats of NWBO
Market
Valuations
Earnings
Shares outstanding
1.39B
Market cap
$295.26M
Enterprise value
$360.52M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
190.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
260.87
Revenue
$1.38M
Gross profit
$1.38M
Operating income
-$66.51M
Net income
-$83.78M
EBIT
-$76.01M
EBITDA
-$73.97M
Free cash flow
-$58.03M
Per share
Balance sheet
Liquidity
EPS
-$0.07
EPS diluted
-$0.07
Free cash flow per share
-$0.05
Book value per share
-$0.07
Revenue per share
$0
TBVPS
$0.02
Total assets
$26.73M
Total liabilities
$105.71M
Debt
$67.44M
Equity
-$94.49M
Working capital
-$64.21M
Debt to equity
-0.71
Current ratio
0.06
Quick ratio
0.03
Net debt/EBITDA
-0.88
Margins
Efficiency
Dividend
EBITDA margin
-5,352.2%
Gross margin
100%
Net margin
-6,062.1%
Operating margin
-4,812.4%
Return on assets
-302%
Return on equity
N/A
Return on invested capital
-386.5%
Return on capital employed
N/A
Return on sales
-5,500.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NWBO stock price
How has the Northwest Biotherapeutics stock price performed over time
Intraday
-7.05%
1 week
-9.7%
1 month
-27.54%
1 year
-59.21%
YTD
-22.74%
QTD
-7.05%
Financial performance
How have Northwest Biotherapeutics's revenue and profit performed over time
Revenue
$1.38M
Gross profit
$1.38M
Operating income
-$66.51M
Net income
-$83.78M
Gross margin
100%
Net margin
-6,062.1%
NWBO's net margin has shrunk by 87% YoY and by 39% QoQ
NWBO's operating margin has dropped by 67% year-on-year and by 22% since the previous quarter
NWBO's net income is down by 34% year-on-year and by 20% since the previous quarter
The company's gross profit fell by 28% YoY and by 13% QoQ
Growth
What is Northwest Biotherapeutics's growth rate over time
Valuation
What is Northwest Biotherapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
190.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
260.87
The EPS has contracted by 17% YoY
The equity has contracted by 44% YoY and by 18% from the previous quarter
The P/S is 61% below the 5-year quarterly average of 522.9 and 35% below the last 4 quarters average of 318.1
Northwest Biotherapeutics's revenue has decreased by 28% YoY and by 13% QoQ
Efficiency
How efficient is Northwest Biotherapeutics business performance
The ROS has plunged by 85% YoY and by 39% from the previous quarter
The return on assets has declined by 42% year-on-year and by 21% since the previous quarter
The ROIC has decreased by 24% QoQ and by 7% YoY
Dividends
What is NWBO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NWBO.
Financial health
How did Northwest Biotherapeutics financials performed over time
The total assets is 75% smaller than the total liabilities
NWBO's total liabilities is up by 41% year-on-year and by 13% since the previous quarter
Northwest Biotherapeutics's quick ratio has decreased by 40% from the previous quarter and by 40% YoY
NWBO's debt is 171% higher than its equity
NWBO's debt is up by 48% YoY and by 16% QoQ
The equity has contracted by 44% YoY and by 18% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.